Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong Sells 14,836 Shares

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 14,836 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $48,662.08. Following the completion of the sale, the chief financial officer now owns 482,572 shares of the company’s stock, valued at approximately $1,582,836.16. This represents a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Neuronetics Stock Up 1.0 %

Shares of STIM traded up $0.04 during trading hours on Wednesday, hitting $3.97. The stock had a trading volume of 867,076 shares, compared to its average volume of 1,610,051. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The firm has a 50 day simple moving average of $2.03 and a 200-day simple moving average of $1.36. The firm has a market capitalization of $120.49 million, a P/E ratio of -3.23 and a beta of 2.17. Neuronetics, Inc. has a 1-year low of $0.52 and a 1-year high of $5.07.

Institutional Trading of Neuronetics

Several large investors have recently made changes to their positions in STIM. Geode Capital Management LLC lifted its position in Neuronetics by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after acquiring an additional 8,466 shares in the last quarter. Tradewinds LLC. bought a new position in Neuronetics in the 4th quarter valued at about $32,000. JPMorgan Chase & Co. lifted its position in Neuronetics by 10,954.1% in the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after acquiring an additional 54,442 shares in the last quarter. David J Yvars Group lifted its position in Neuronetics by 47.1% in the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after acquiring an additional 14,825 shares in the last quarter. Finally, HighTower Advisors LLC lifted its position in Neuronetics by 55.5% in the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock valued at $187,000 after acquiring an additional 87,816 shares in the last quarter. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.